In a promising scientific breakthrough that could mark a turning point in obesity treatment, researchers have discovered a new compound called SANA, which has shown remarkable results in early trials on both animals and humans. This compound, derived from salicylic acid as the main component of aspirin was originally being developed to treat inflammation. However, scientists were surprised to find it highly effective not only in preventing weight gain but also in promoting weight loss, even among subjects consuming high-fat diets.
What sets SANA apart from other obesity drugs, such as GLP-1-based medications like semaglutide, is its unique mechanism of action. Rather than simply suppressing appetite, SANA activates the body’s internal heat production known as thermogenesis which burns calories to produce heat. Remarkably, SANA stimulates this process without relying on the usual protein UCP1. Instead, it triggers an alternative pathway involving creatine, making its action on fat tissue more precise and safer, without affecting muscle mass or causing harmful increases in body temperature.
The early clinical results have been extremely encouraging. In the first phase of human clinical trials, which included various doses administered to overweight or obese volunteers, participants showed significant improvements in insulin sensitivity and weight loss within just two weeks, and without experiencing any serious side effects. These results were notably stronger than those achieved by salicylic acid alone, according to researcher Carlos Escande of the Pasteur Institute.
SANA’s potential is further enhanced by its ability to work synergistically with existing drugs like semaglutide. Because its action is different, it could be paired with appetite-suppressing drugs to overcome the common “weight loss plateau” effect many experience during dieting. Moreover, SANA does not cause muscle loss as a critical advantage, especially for elderly individuals.
The key to SANA’s effect lies in its active chemical group, known as a nitroalkene, which activates several cellular pathways involved in energy production and mitochondrial efficiency in fat cells. Studies have also shown that SANA enhances the creatine cycle a cellular energy conversion process that generates heat without placing stress on the body.
Although the initial findings are promising, researchers stress that the results are not yet conclusive. The primary goal of the first phase was to test the drug’s safety, not its large-scale effectiveness. Phase two of the clinical trials is expected to begin later this year and will aim to evaluate the compound’s efficacy on a broader group of participants.
If future trials confirm its effectiveness, SANA could become the first in a new class of obesity treatments, offering a safer and more effective alternative for millions of people worldwide struggling with this chronic and complex condition.